LivaNovaLIVN +1.40%76 Beneish M-Score is -2.42 as of Jun. 25, 2026. GuruFocus rates LIVN with a GF Score™ of 76/100 and a GF Value™ of $62.48 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 766 Medical Devices & Instruments companies, LivaNova ranks worse than 62.79% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.42 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for LivaNova's Beneish M-Score or its related term are showing as below:
LIVN'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.16 Med: -2.63 Max: 2.5
Current: -2.42
During the past 13 years, the highest Beneish M-Score of LivaNova was 2.50. The lowest was -3.16. And the median was -2.63.
LivaNova Beneish M-Score Related Terms
LivaNova Beneish M-Score Historical Data
* Premium members only.
The historical data trend for LivaNova's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LIVN vs IRTC, HAE, ITGR: Beneish M-Score Comparison
For the Medical Devices subindustry, LivaNova's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LivaNova Beneish M-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where LivaNova's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of LivaNova for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.0403
+
0.528 * 1.0069
+
0.404 * 1.0435
+
0.892 * 1.124
+
0.115 * 1.1572
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.9781
+
4.679 * -0.039054
-
0.327 * 0.836
=
-2.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(52.676 / (52.676 + 225.841))
/
(60.561 / (60.561 + 310))
=
0.18913
/
0.163431
=
1.1572
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(107.151 - -40.147
-
245.574)
/
2516.4
=
-0.039054
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
LivaNova has a M-score of -2.42 suggests that the company is unlikely to be a manipulator.
LivaNova (LIVN) has a Beneish M-Score of -2.42 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on LivaNova and its competitors. According to the industry distribution chart, LivaNova ranks #481 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 62.8%.
Is LivaNova's Beneish M-Score too high?
LivaNova's current Beneish M-Score is -2.42. Based on the distribution chart, LivaNova ranks #481 out of 766 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, LivaNova has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LivaNova's Beneish M-Score compare to IRTC and HAE?
According to the Medical Devices & Instruments industry distribution chart, LivaNova ranks #481 out of 766 companies for Beneish M-Score. This places LivaNova in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on LivaNova and its competitors. LivaNova's current Beneish M-Score is -2.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LivaNova stock overvalued right now?
Based on GuruFocus' analysis, LivaNova (LIVN) is currently considered Modestly Overvalued. The stock's GF Value™ is $62.48, compared to a current price of $81.05 — trading 29.7% above its estimated fair value. The current Beneish M-Score is -2.42. LivaNova's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For LivaNova (LIVN), the current Beneish M-Score is -2.42 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LivaNova (LIVN) Overvalued in 2026?
Based on GuruFocus' analysis, LivaNova stock appears to be overvalued.
The current stock price of $81.05 is trading 29.7% above its estimated GF Value™ of $62.48.
GuruFocus considers LivaNova to be Modestly Overvalued.
Key valuation signals for LIVN:
Beneish M-Score: -2.42
GF Value™: $62.48 vs. price of $81.05 (29.7% above fair value)
No single metric tells the full story. See the LIVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
76GF Score
Get the complete analysis for LIVN
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIVN has been successfully added to your 
